Preclinical Efficacy and Intermediate Endpoint Biomarkers
Ended Master IDIQ Awarded
- Federal agency
-
National Institutes of Health
- Awardees
- 4
- Task orders
- 21
- Obligated
- $9,613,897
Vehicle facts
- Opportunity
-
- N01CN2500278 Solicitation number
- Agency
-
- National Institutes of Health Department of Health and Human Services
- Combined task order value
- $9,614,395 Current and potential, with all options
- Last date to order 100% complete
- Shared ceiling 97% used
- $9,950,000.00
IDV award and task order details come from SAM.gov/FPDS.
About this vehicle
The National Institutes of Health established this Master IDIQ on September 20, 2012, to evaluate the efficacy of chemopreventive regimens and identify pharmacodynamic and efficacy biomarkers for clinical trial development, with a combined potential value of $9.6 million. Ordering closed on October 29, 2015, and the vehicle is no longer active — the most recent task order was awarded September 18, 2014.
All 21 task orders issued under the vehicle went to the National Cancer Institute, making customer concentration absolute. University of Oklahoma dominated the prime contractor base, capturing 10 orders worth $5 million combined potential value—roughly 52% of all activity. The Institute For Cancer Research and IIT Research Institute held 6 orders ($2.6 million) and 3 orders ($1.3 million) respectively, with Sri International accounting for the remaining 2 orders ($645 thousand). No small-business set-asides were used; all work was unrestricted competitive.
Task orders ranged from modest ($3,709 for a contract orientation meeting) to mid-size research efforts. Representative orders included $567,649 for modulation of miRNA expression in blood and tissue under cigarette smoke and NSAID exposure; $907,864 for multi-antigen vaccine development for lung cancer prevention; $685,413 for chemoprevention of prostate cancer via estrogen receptor beta agonists; and $641,280 for mesothelin vaccination for ovarian cancer prevention. Orders typically ran two to three years. The vehicle obligated its entire $9.6 million potential value across 21 awards, with ordering momentum declining sharply in 2014 (5 orders that year versus 8 in each of 2012 and 2013).
Work focused on preclinical cancer prevention research using animal models to test candidate chemopreventive agents, identify biomarkers, and evaluate vaccine approaches across multiple cancer types including lung, pancreatic, colon, ovarian, prostate, and oral cancer. Most orders used firm fixed-price or cost-no-fee pricing. This vehicle is closed to new orders and represents a completed, fully obligated portfolio.
Description
Master IDIQ for evaluating the efficacy of potential chemopreventive regimens as well as to identifypharmacodynamic and or efficacy biomarkers which will enhance the development of these regimens for clinicaltrials.
IDV awards
Latest task orders
Show all 21
Top awardees by obligations
| Rank | Awardee | Obligated | Share |
|---|---|---|---|
| 1 | University Of Oklahoma | $5,027,799 | 52% |
| 2 | The Institute For Cancer Research | $2,632,795 | 27% |
| 3 | IIT Research Institute | $1,308,376 | 14% |
| 4 | Sri International | $644,927 | 7% |
Top funding agencies by obligations
| Rank | Funding agency | Obligated | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $9,613,897 | 100% |
Obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2019 | -$103 |
| FY2018 | -$12,193 |
| FY2017 | -$11,342 |
| FY2016 | -$2,771 |
| FY2014 | $3,235,853 |
| FY2013 | $4,226,089 |
| FY2012 | $2,178,364 |
Quick answers
What is the Preclinical Efficacy and Intermediate Endpoint Biomarkers contract vehicle?
Preclinical Efficacy and Intermediate Endpoint Biomarkers is an indefinite delivery, indefinite quantity (IDIQ) contract vehicle run by National Institutes of Health (Department of Health and Human Services), awarded on September 20, 2012.
Which companies hold Preclinical Efficacy and Intermediate Endpoint Biomarkers?
4 companies hold Preclinical Efficacy and Intermediate Endpoint Biomarkers's IDV awards, one each. The latest went to The Institute For Cancer Research on September 20, 2012. The awardees whose task orders obligated the most are University Of Oklahoma, The Institute For Cancer Research and IIT Research Institute.
How much has been spent through Preclinical Efficacy and Intermediate Endpoint Biomarkers?
21 task orders have been placed under Preclinical Efficacy and Intermediate Endpoint Biomarkers, obligating $9,613,897. Their combined current value, with exercised options, is $9,614,395.
What is the shared ceiling of Preclinical Efficacy and Intermediate Endpoint Biomarkers?
Preclinical Efficacy and Intermediate Endpoint Biomarkers's shared ceiling is $9,950,000; its task orders have used 97% of it.
Which agencies use Preclinical Efficacy and Intermediate Endpoint Biomarkers the most?
The departments whose task orders under Preclinical Efficacy and Intermediate Endpoint Biomarkers obligated the most are Department of Health and Human Services ($9,613,897).
On GovTribe
See this vehicle's full record
- Every IDV award and task order
- Funding by agency, awardee, NAICS and set-aside
- Teaming partners on this vehicle
- Ask GovTribe AI about this vehicle